AVEN and leukemia: DHX36 has been implicated in leukemia through interaction with apoptosis and caspase activation inhibitor, AVEN, to increase translation of leukemogenic transcriptional regulators MLL1 and MLL4, and subsequent proliferation of leukemic cells [65].